# Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy

> **NCT04183101** · PHASE2 · RECRUITING · sponsor: **Region Skane** · enrollment: 30 (estimated)

## Conditions studied

- C3 Glomerulopathy
- Membranoproliferative Glomerulonephritis
- Complement Abnormality
- Dense Deposit Disease
- C3 Glomerulonephritis

## Interventions

- **DRUG:** Aliskiren
- **DRUG:** Enalapril

## Key facts

- **NCT ID:** NCT04183101
- **Lead sponsor:** Region Skane
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-10-01
- **Primary completion:** 2029-12
- **Final completion:** 2029-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04183101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04183101, "Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04183101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*